Company profile: DiaMedica Therapeutics
1.1 - Company Overview
Company description
- Provider of biopharmaceutical R&D focused on treatments for stroke, developing DM199, a recombinant human tissue kallikrein-1 (KLK1) intended to treat acute ischemic stroke and cardio-renal diseases by restoring KLK1 levels, and conducting the ReMEDy2 adaptive, randomized, double-blind, placebo-controlled trial to study DM199’s efficacy and safety in acute ischemic stroke.
Products and services
- ReMEDy2 Trial: Adaptive-design, randomized, double-blind, placebo-controlled study evaluating DM199’s efficacy and safety in treating acute ischemic stroke patients
- DM199—Acute Ischemic Stroke: Recombinant human tissue kallikrein-1 (KLK1) therapy intended to treat acute ischemic stroke by restoring normal KLK1 levels
- DM199—Cardio-Renal Diseases: Recombinant human tissue kallikrein-1 (KLK1) therapy intended to treat cardio-renal diseases by restoring normal KLK1 levels
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to DiaMedica Therapeutics
Navitor Pharmaceuticals
HQ: United States
Website
- Description: Provider of novel medicines targeting nutrient-sensing proteins, including NV-5138, an orally bioavailable small molecule that directly activates mTORC1 for treatment-resistant depression, and AT-20494, a selective mTORC1 inhibitor for autosomal dominant polycystic kidney disease and potentially other conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Navitor Pharmaceuticals company profile →
EdenRoc Sciences
HQ: United States
Website
- Description: Provider of holding and operating services for bioscience and pharmaceutical startups, managing Metro International Biotech (proprietary NAD boosters), Cantata Bio (NGS-based multiomics tools via Dovetail Genomics and Arc Bio), Claret Bioscience, Astrea Forensics (advanced DNA for casework), Delavie Sciences (consumer care ingredients), and Liberty Biosecurity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full EdenRoc Sciences company profile →
Pernix Therapeutics
HQ: United States
Website
- Description: Provider of branded and generic pharmaceutical products for the pediatric market, specializing in the sales, marketing, and development of products designed to improve children's health and well-being, including offerings in allergy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pernix Therapeutics company profile →
Sunovion
HQ: United States
Website
- Description: Provider of therapeutic products discovered, developed and commercialized for central nervous system and respiratory disorders and other illnesses. Portfolio includes Latuda for schizophrenia and bipolar depression; Aptiom for partial-onset seizures; Gemtesa/vibegron for overactive bladder; Myfembree for heavy menstrual bleeding due to uterine fibroids; Orgovyx for advanced prostate cancer; LUNESTA; and XOPENEX.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sunovion company profile →
Rexahn Pharmaceuticals
HQ: United States
Website
- Description: Provider of treatments for cancer, central nervous system disorders, and other unmet medical needs in the United States.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rexahn Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for DiaMedica Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to DiaMedica Therapeutics
2.2 - Growth funds investing in similar companies to DiaMedica Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for DiaMedica Therapeutics
4.2 - Public trading comparable groups for DiaMedica Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →